Inmune Bio (INMB) Accounts Payables (2017 - 2025)
Historic Accounts Payables for Inmune Bio (INMB) over the last 9 years, with Q3 2025 value amounting to $6.9 million.
- Inmune Bio's Accounts Payables fell 3508.03% to $6.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.9 million, marking a year-over-year decrease of 3508.03%. This contributed to the annual value of $6.5 million for FY2024, which is 1723.83% down from last year.
- According to the latest figures from Q3 2025, Inmune Bio's Accounts Payables is $6.9 million, which was down 3508.03% from $7.7 million recorded in Q2 2025.
- In the past 5 years, Inmune Bio's Accounts Payables registered a high of $10.6 million during Q3 2024, and its lowest value of $1.6 million during Q1 2021.
- In the last 5 years, Inmune Bio's Accounts Payables had a median value of $4.2 million in 2021 and averaged $5.2 million.
- As far as peak fluctuations go, Inmune Bio's Accounts Payables surged by 34747.23% in 2024, and later tumbled by 3508.03% in 2025.
- Inmune Bio's Accounts Payables (Quarter) stood at $3.7 million in 2021, then soared by 39.46% to $5.2 million in 2022, then surged by 51.77% to $7.9 million in 2023, then fell by 17.24% to $6.5 million in 2024, then rose by 5.14% to $6.9 million in 2025.
- Its last three reported values are $6.9 million in Q3 2025, $7.7 million for Q2 2025, and $7.2 million during Q1 2025.